Cumberland Pharmaceuticals (CPIX) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed TuHURA Biosciences (HURA) over the past year, gaining 108.7% versus a loss of 26.7%. Over five years, CPIX leads with a +167.9% price change compared with -99.9% for HURA. TuHURA Biosciences is the larger company by market cap ($112.2 million vs $107.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | HURA |
|---|---|---|
| Share price | $7.18 | $1.76 |
| Market cap | $107.58M | $112.16M |
| 1-day change | -4.77% | -3.83% |
| YTD return | +80.40% | +132.50% |
| 1-year return | +108.72% | -26.67% |
| 5-year return | +167.91% | -99.89% |
| Forward P/E | 51.29 | — |
| EPS (TTM) | $-0.62 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.52M | $0 |
| Revenue growth (YoY) | +17.57% | — |
| Net income (latest FY) | $-2.84M | $-30.05M |
| Gross margin | 85.02% | — |
| Operating margin | -6.27% | — |
| Net margin | -6.37% | — |
| 52-week high | $9.28 | $3.43 |
| 52-week low | $1.85 | $0.41 |
| Distance from 52-week high | -22.63% | -48.69% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +356.82% |
| Average volume | 76.95K | 221.74K |
| Shares outstanding | 14.98M | 63.73M |
| Employees | 88 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed HURA by 135.4 percentage points over the past year.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
CPIX vs HURA FAQ
Which is bigger, Cumberland Pharmaceuticals or TuHURA Biosciences?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $112.16M compared with $107.58M for Cumberland Pharmaceuticals (CPIX).
Which stock has performed better over the past year, CPIX or HURA?
CPIX returned +108.72% over the past 12 months, compared with -26.67% for HURA (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.